Skip to main content
OpenTrials
Completed

NCT Number: NCT02774499

Preoperative Oral Methadone for Patients Undergoing Cardiac Surgery: Reduction of Postoperative Pain

Oral medications like gabapentin and acetaminophen are commonly given to patients prior to surgery to provide balanced anaesthesia. Intravenous methadone has been shown to decrease postoperative pain as well as postoperative nausea and vomiting, which are known barriers to discharge. Oral methadone would be a convenient alternative to give as a preoperative medication with its bioavailability approaching 80%. No clinical trials to date have explored the utility of oral methadone as a preoperative analgesic to improve postoperative outcomes. Current literature shows preoperative IV methadone reduces opioid consumption in the perioperative period for cardiac surgeries; therefore, investigators hypothesize that preoperative oral methadone will also reduce postoperative pain and opioid consumption in patients undergoing sternotomy for cardiac surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Saskatoon Health Region, 410 22nd Street East

Saskatoon, Saskatchewan, S7K 5T6, Canada

About this study

Investigators propose a prospective, randomized, double-blind, placebo-controlled trial to investigate the effects of preoperative oral methadone on postoperative pain. The trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and University of Saskatchewan Research Ethics Committee principles using an intent-to-treat model. The primary endpoint will be postoperative pain in the ICU, and secondary outcomes will include morphine requirements as measured by Patient Controlled Analgesia (PCA). Secondary endpoints include opioid consumption at 15 minutes and at 2, 4, 8, 12, 24, 48, and 72 hours post extubation. Other secondary endpoints include the following: pain with cough (using a 0-10 verbal pain scale) measured at the time of extubation then daily until post-op day three. Secondary outcomes that will be recorded from nursing assessment records include: incidence of nausea and/or vomiting requiring antiemetics, pruritus, hypoventilation (respiratory rate less than 8 breaths/min), hypoxemia (oxygen saturation less than 90%), time to extubation, and sedation (Richmond Agitation-Sedation Scale of -4 or -5).

Patients will receive a dose of either oral methadone or placebo prior to entering the operating room. The dose given will be 0.3 mg/kg (to a maximum of 30 mg) or equivalent volume of placebo. An blinded research assistant will receive an envelope the morning of surgery outlining if the patient is in group A or B as well as their weight in kg. For the methadone arm the research assistant will prepare the appropriate amount of methadone, which is dispensed as 10 mg/mL, and dilute it to a total volume of 5 mL in sugary syrup to mask its taste. For the placebo arm a similar volume will be mixed at a 0.3 mg/kg volume and diluted to a total volume of 5 mL of sugary syrup. The methadone or placebo will be given to the researcher in a syringe. The researcher will give syringe to the patient and the patient will administer the solution to themself orally prior to entering the operating room.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • presenting for elective first-time CABG cardiac surgery with anticipated extubation within 12 hours

Exclusion criteria

  • < 18 years of age
  • preoperative renal failure requiring dialysis or serum creatinine greater than 176 µmol/L
  • significant hepatic dysfunction (liver function tests more than twice the upper limit of normal)
  • ejection fraction less than 30%
  • corrected QT interval (QTc) on ECG > 440ms for men and 450ms for women
  • pulmonary disease necessitating home oxygen therapy
  • preoperative requirement for inotropic agents or intra-aortic balloon pump to maintain hemodynamic stability
  • emergency surgery
  • allergy to methadone
  • use of preoperative opioids or recent history of opioid abuse

Treatment and study plan

Methadone

Drug

0.3mg/kg of methadone given preoperatively (to maximum of 30mg)

Placebo

Drug

equivalent volume (5mL) of syrup given preoperatively

Primary outcomes

  1. Pain score (VRS)

    Time frame: 24 hours

    Pain score as measured by 0-10 Verbal Rating Score (VRS)

Secondary outcomes

  1. Total Morphine Consumption (mg)

    Time frame: 72 hours

    Total dose in mg of IV morphine administered via Patient Controlled Analgesia

  2. Pain score (VRS)

    Time frame: Up to 72 hours postoperative

    Pain score as measured by 0-10 Verbal Rating Score (VRS)

  3. Time to extubation

    Time frame: up to 24 hours postoperative

    Time from start of surgery until removal of endotracheal tube in ICU

  4. Level of sedation

    Time frame: up to 72 hours postoperative

    Level of sedation as measured by the Richmond Agitation-Sedation Scale (RASS) in ICU

  5. Incidence of opioid-related side effects

    Time frame: up to 72 hours postoperative

    Incidence of as nausea, vomiting, pruritus, hypoventilation, and hypoxia during a seventy-two hour monitoring period

Sponsors and collaborators

Lead sponsor

University of Saskatchewan

Other

Registry information

Important dates

Study start
2016
Primary completion
2016
Study completion
2017
First posted
May 17, 2016
Registry last updated
Jan 2, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.